Faeth Therapeutics (FTH) Enterprise Value (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Enterprise Value came in at $125.7 million in Q1 2026, up 466.09% YoY from $22.2 million in Q1 2025, and up 693.29% on a QoQ basis from -$21.2 million in Q4 2025.
Faeth Therapeutics (FTH) Enterprise Value (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Enterprise Value data on file, last reported at $125.7 million in Q1 2026.
- Quarterly Enterprise Value rose 466.09% year-over-year to $125.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.7 million (up 466.09% YoY) and the FY2025 annual result came in at -$21.2 million, up 48.75% from the prior year.
- Enterprise Value grew to $125.7 million in Q1 2026, from -$21.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $125.7 million in Q1 2026 to a low of -$136.2 million in Q1 2022.
- A 5-year average of -$57.5 million and a median of -$58.1 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value advanced 19.59% — and 2026, when it soared 466.09%.
- Tracing FTH's Enterprise Value over 5 years: stood at -$107.1 million in 2022, then jumped by 38.61% to -$65.8 million in 2023, then jumped by 37.14% to -$41.3 million in 2024, then soared by 48.75% to -$21.2 million in 2025, then surged by 693.29% to $125.7 million in 2026.
- The last three Enterprise Value figures came in at $125.7 million (Q1 2026), -$21.2 million (Q4 2025), and -$25.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | -179.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -179.67 Mn |
| Mar 31, 2026 | 125.68 Mn |
| Dec 31, 2025 | -21.18 Mn |
| Sep 30, 2025 | -25.04 Mn |
| Jun 30, 2025 | -28.63 Mn |
| Mar 31, 2025 | -34.33 Mn |
| Dec 31, 2024 | -41.34 Mn |
| Sep 30, 2024 | -47.00 Mn |
| Jun 30, 2024 | -52.29 Mn |
| Mar 31, 2024 | -58.08 Mn |
| Dec 31, 2023 | -65.76 Mn |
| Sep 30, 2023 | -72.01 Mn |
| Jun 30, 2023 | -78.84 Mn |
| Mar 31, 2023 | -95.51 Mn |
| Dec 31, 2022 | -107.12 Mn |
| Sep 30, 2022 | -116.56 Mn |
| Jun 30, 2022 | -123.71 Mn |
| Mar 31, 2022 | -136.22 Mn |
| Dec 31, 2021 | -147.62 Mn |
| Sep 30, 2021 | -156.66 Mn |